News for Sutro Biopharma, Inc. (STRO)

Sutro Biopharma (STRO) has announced a collaboration with the U.S. Food and Drug Administration (FDA) to enhance the development framework for antibody-drug con

Sutro Biopharma (STRO) collaborates with the FDA to enhance regulatory standards for Antibody Drug Conjugates (ADCs). The partnership will use Sutro's p

On June 16, 2025, Sutro Biopharma (STRO) received an analyst rating upgrade from Piper Sandler. The analyst, Edward Tenthoff, has upgraded the stock from a "Neu

Sutro Biopharma (STRO) has been upgraded by Piper Sandler from a Neutral to an Overweight rating, though the price target remains at $2. This change reflects op

Investment firm Piper Sandler has elevated Sutro Biopharma (STRO) from a Neutral to an Overweight rating, while maintaining a price target of $2. This upgrade s

Sutro Biopharma (STRO) has named Greg Chow as its Chief Financial Officer, effective June 2, 2025. Before joining Sutro, Chow held the position of Chief Financi

SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) ( STRO), an oncology company pioneering site-speci

On May 19, 2025, B of A Securities analyst Tazeen Ahmad maintained the rating on Sutro Biopharma (STRO) as "Underperform." This rating remains unchanged from th

Revenue: $17.4 million for Q1 2025, surpassing the estimated $11.61 million and up from $13.0 million in Q1 2024.Net Loss: $75.97 million for Q1 2025, compared

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (STRO) reports a strong cash position of $249.0 million, extending its runway into early 2027. The company shifts focus to its next-gene

**media[619715]**

**media[618065]**

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) ( STRO), an oncology company pioneering site-specif

PR NewswireVANCOUVER, BC, May 1, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, May 1, 2025 /PRNewswire/ -- E

SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. ( PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humanki

- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSW

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce tariffs on the industry soon.

**media[580791]**